p16 INK4a and the Alveolar Niche Take Center Stage in Bronchopulmonary Dysplasia

Bronchopulmonary dysplasia (BPD) is a common pulmonary complication of prematurity, resulting in long-term pulmonary morbidity or death. BPD is conceptually understood as an irreversible growth arrest of the premature lung caused by multiple pre- and postnatal injurious events leading to two main histomorphological characteristics: alveolar simplification and dysmorphic pulmonary vasculature. The incidence of BPD is approximately 40% and still increasing, leading to a substantial burden for patients and healthcare systems (1). Yet, there is no curative therapy available. Thus, concepts to promote pulmonary regeneration are urgently needed. In this context, a study in this issue of the Journal demonstrates the capacity of the lung to resume alveolar development after significant hyperoxia injury. This study also suggests that a key mesenchymal cell type is critical for this regenerative process.

In this issue of the Journal, Zysman and colleagues (pp. 1088–1104) evaluate the dynamics of the cell-cycle kinase inhibitor p16 (also known as p16 INK4a or cyclin-dependent kinase inhibitor 2A) in a murine hyperoxia model (2). The authors observed an increase in p16-positive nuclei in the lung tissue from mice exposed to high oxygen conditions. Next, they found that deficiency of p16 INK4a enhances lung regeneration following hyperoxia-induced lung injury as well as after pneumonectomy, a model of compensatory growth in adult lung. They show that p16 deficiency restores normal lung architecture into adulthood but does not protect against early hyperoxia-induced lung injury. A similar trend is observed when p16 INK4a-expressing cells are depleted after hyperoxia conditions. Interestingly, the authors show that the number of Pdgfra (platelet-derived growth factor α)-positive fibroblasts and an associated lipid profile (lipid-content staining and ADRP expression) are significantly increased in p16 INK4a-deficient animals (see interaction 1 in Figure 1). In line with the restored alveolar tissue, the authors also find an increase in the number of alveolar type 2 (AT2) cells. Together, these data underscore the capacity for tissue repair in the lung alveolus and highlight cell dynamics acting in parallel between the alveolar mesenchyme and epithelium.

The cellular and functional heterogeneity within the mesenchyme, including fibroblasts and smooth muscle, has been under intense investigation in multiple organs. Recent studies have relied on new tools for genetic lineage tracing as well as single-cell transcriptomics to dissect fibroblast subsets and their associated function. In the lung alveolar compartment, electron microscopy and histology were used to characterize fibroblasts with lipid droplets, termed lipofibroblasts (LIFs), in rodents. Furthermore, these lipid droplet–containing mesenchymal cells were mapped in close proximity to AT2 cells (3). Zysman and colleagues found an increase in LIFs and enriched set of genes implicated in lipid content and storage from whole-lung homogenates as well as an enhanced neutral lipid profile in the p16 INK4a knockouts. Transgenic and knock-in mouse lines have further shown that the resident alveolar fibroblasts are mostly composed of Pdgfra- or Pdgfrb-expressing cells. Interestingly, in three-dimensional alveolar epithelial organoid models, Pdgfra fibroblasts, which includes LIFs, but not Pdgfrb fibroblasts, have the unique ability to support alveolar epithelial organoid growth and differentiation (4, 5). These data indicate that alveolar fibroblasts may be functionally classified by their abilities to support epithelial cell growth. Thus, they have been referred to as mesenchymal alveolar niche or (alveolar) type 2–associated stromal cells (see interaction 2 in Figure 1) (5, 6). Taken together, future work will be needed to determine the relevance of a lipid-associated profile and alveolar cell growth and differentiation.

Extracellular ligands such as leptin, retinoic acid, Pthrp (parathyroid hormone-related protein), Fgf (Fg7/Fg10), cytokines, Bmp (bone morphogenic protein) antagonists, and Wnt ligands have been implicated in the fibroblast/AT2 cell niche (5, 7–9). Furthermore, a Wnt/Fgf responsive subset of AT2 cells has been shown to exhibit enhanced progenitor capabilities (8, 9). The data presented by Zysman and colleagues suggests that the increased numbers of lipofibroblast/AT2 may restore alveolar repair after hyperoxia. However, whether p16 INK4a actively inhibits the proliferation of LIFs and/or impairs their capacity to sustain the AT2 progenitor cells via the content of secreted ligands is unclear.

In injury models, including the hyperoxia model used by Zysman and colleagues, it is not unexpected that the expression levels of p16 INK4a, a potent cell cycle inhibitor, increases, possibly because of underlying cell stress in response to reactive oxygen species. The key findings from Zysman and colleagues indicate that clearance of the cells expressing p16 INK4a results in a significant improvement across a variety parameters of lung function and that alveolar fibroblasts are sensitive to this cell cycle regulation. The latter finding raises many additional questions or clarifications, including what mechanisms, transcriptional signatures, and pathways are active in distinct subsets of lung fibroblasts, and are these critical for cell identity? Addressing these questions would also require a thorough characterization of the proliferation, expansion, and contraction of specific mesenchymal cell subsets.
In particular, it will be important to better characterize the $\text{p16}^{\text{INK4a}}$-positive fibroblast population in terms of heterogeneity, identification of specific surface markers, and signaling pathway activity.

Insights into the lineage relationship between alveolar fibroblasts and myofibroblasts might offer clues for targeted therapies to promote alveologenesis after lung injury. The concept of LIF transdifferentiating to myogenic cell types such as the myofibroblast (MYF) was pioneered almost 20 years ago. Using molecular and metabolic studies, it was suggested that a transdifferentiation of LIFs to MYFs occurs upon hyperoxia-induced lung injury (10). Whether the MYFs in question in this study were alveologenesis-specific secondary crest myofibroblasts (SCMF) or activated (pathogenic) MYFs was not shown (see interactions 3 and 4 in Figure 1). Recently, a reversible switch of LIF to activated MYF in idiopathic pulmonary fibrosis was reported (11). In a follow-up study, the metabolic drug Metformin was shown to induce lipogenic differentiation in activated MYFs to reverse lung fibrosis (see interaction 4 in Figure 1) (12).

Interestingly, it was proposed that Pdgfra-positive/LIF cells could give rise to MYFs during realveolarization after pneumonectomy (see interaction 4 in Figure 1) (13).

How AT2s interact with other mesenchymal cell types such as the SCMF is currently unknown (see interaction 5 in Figure 1). It was recently demonstrated using a cell-autonomous approach that overexpression of $\text{miR-154}$ in AT2 cells leads to defective alveologenesis, suggesting that AT2 cells could be instrumental in this developmental process (14). In this context, it will be interesting to define the link between the LIF-AT2 interaction upon deletion of $\text{p16}^{\text{INK4a}}$-positive fibroblasts and the process of alveologenesis, particularly whether AT2s impact the formation and/or the functionality of SCMFs. BPD results from the disruption of intricate processes underlying the development of the alveolar tissue. The current study and new questions may help to address the paucity of information regarding the cell turnover and differentiation of the mesenchyme and the impact on the alveolar niche.

Figure 1. Modeling $\text{p16}^{\text{INK4a}}$ expression in the context of the developing alveolar niche. (Interaction 1) Zysman and colleagues show that under hyperoxic conditions fibroblasts express $\text{p16}^{\text{INK4a}}$. Fibroblasts that are Pdgfra positive and express $\text{p16}^{\text{INK4a}}$ display an increased lipid profile. It has been shown that Pdgfra-positive fibroblasts support AT2 cell self-renewal via an exchange of secreted factors (interaction 2).

(see interaction 1 in Figure 1). In particular, it will be important to better characterize the $\text{p16}^{\text{INK4a}}$-positive fibroblast population in terms of heterogeneity, identification of specific surface markers, and signaling pathway activity.

Insights into the lineage relationship between alveolar fibroblasts and myofibroblasts might offer clues for targeted therapies to promote alveologenesis after lung injury. The concept of LIF transdifferentiating to myogenic cell types such as the myofibroblast (MYF) was pioneered almost 20 years ago. Using molecular and metabolic studies, it was suggested that a transdifferentiation of LIFs to MYFs occurs upon hyperoxia-induced lung injury (10). Whether the MYFs in question in this study were alveologenesis-specific secondary crest myofibroblasts (SCMF) or activated (pathogenic) MYFs was not shown (see interactions 3 and 4 in Figure 1). Recently, a reversible switch of LIF to activated MYF in idiopathic pulmonary fibrosis was reported (11). In a follow-up study, the metabolic drug Metformin was shown to induce lipogenic differentiation in activated MYFs to reverse lung fibrosis (see interaction 4 in Figure 1) (12).

Interestingly, it was proposed that Pdgfra-positive/LIF cells could give rise to MYFs during realveolarization after pneumonectomy (see interaction 4 in Figure 1) (13).

How AT2s interact with other mesenchymal cell types such as the SCMF is currently unknown (see interaction 5 in Figure 1). It was recently demonstrated using a cell-autonomous approach that overexpression of $\text{miR-154}$ in AT2 cells leads to defective alveologenesis, suggesting that AT2 cells could be instrumental in this developmental process (14). In this context, it will be interesting to define the link between the LIF-AT2 interaction upon deletion of $\text{p16}^{\text{INK4a}}$-positive fibroblasts and the process of alveologenesis, particularly whether AT2s impact the formation and/or the functionality of SCMFs. BPD results from the disruption of intricate processes underlying the development of the alveolar tissue. The current study and new questions may help to address the paucity of information regarding the cell turnover and differentiation of the mesenchyme and the impact on the alveolar niche.

Author disclosures are available with the text of this letter at www.atsjournals.org.

Cho-Ming Chao, M.D., Ph.D.
Universities of Giessen and Marburg Lung Center, Member of the German Center for Lung Research (DZL)
Justus Liebig University Giessen
Giessen, Germany

Saverio Bellusci, Ph.D.
Universities of Giessen and Marburg Lung Center, Member of the German Center for Lung Research (DZL)
Justus Liebig University Giessen
Giessen, Germany

and

Developmental Biology and Regeneration Program
Children’s Hospital Los Angeles/University of Southern California
Los Angeles, California

Jarod A. Zepp, Ph.D.
Department of Pediatrics
Children’s Hospital of Philadelphia/University of Pennsylvania
Philadelphia, Pennsylvania
Activation of Group 2 Innate Lymphoid Cells via TL1A/DR3: A Solution to Corticosteroid Resistance?

Airway type 2 inflammation in asthma is associated with enhanced steroid responsiveness, though a large proportion of nonresponders have eosinophilic asthma at baseline, which persists despite treatment. In addition to poor medication compliance, type 2 cytokines may further contribute biologically to this phenomenon; IL-5 delays or inhibits eosinophil apoptosis (1), whereas IL-13 may suppress steroid-mediated downregulation of LPS-induced IL-6 production by monocytes (2). In this issue of the Journal, Machida and colleagues (pp. 1105–1114) shed light on the role of the TL1A/DR3 (death receptor 3) axis in group 2 innate lymphoid cell (ILC2) activation in asthma and thus pinpoint the potential of this pathway as a therapeutic target for modulation of eosinophilia in those with severe asthma (3).

ILCs consist of a highly heterogeneous and functionally diverse group of cells, which at barrier surfaces are capable of rapidly responding to microbial and other antigenic stimuli. Humans and mice may differ significantly, with circulating ILC progenitors constitutively present in human peripheral blood and differentiating into mature ILCs within tissues (4). ILC2s express GATA-3 and produce the cytokines IL-4, IL-5, IL-9, IL-13, and amphiregulin in response to pathogens or other stimuli (5, 6) while they are responsive to IL-25, TSLP, and IL-33, among other mediators. Impaired regulation of such responses may drive allergic disease such as asthma, allergic rhinitis, and atopic dermatitis (6, 7). ILC2-derived IL-4, for example, plays a role in the inhibition of Treg cell responses (7), and ILC2s produce IL-2 after allergen challenge. Furthermore, human ILC2s express MHC class II molecules and present allergen-derived peptides to CD4+ T cells, leading to differentiation and propagation of Th2 cell subsets (8). In relation to asthma, initial studies were performed in murine models (5, 6), whereas later increased numbers of ILC2s have been identified in the sputum and BAL of patients with severe eosinophilic asthma compared with control subjects (9). Activated ILC2s also rapidly increase in the airways after allergen challenge (10). ILC2s may have an even more substantial role in the persistence of airway eosinophilia among patients with severe asthma through uncontrolled localized production of type 2 cytokines despite high-dose oral corticosteroid therapy (9). Yet, there is an accentuated need for further research regarding